Plethico Pharmaceutical is looking at trimming its Contract Research and Manufacturing Services (CRAMS) business as low margins are being further squeezed out due to higher inflation and surging crude oil prices.
Economic Times
Monday, 30 June 2008
Plethico plans to cut CMO business
Emcure inaugurates plants
Indian manufacturer, Emcure Pharmaceuticals, has inaugurated its commercial oncology products manufacturing plant in Hinjewadi. In addition, Emcure's Gennova Biopharmaceuticals subsidiary has inaugurated its trial-scale malaria vaccine manufacturing facility.
Economic Times
Sunday, 29 June 2008
Thursday, 26 June 2008
Wednesday, 25 June 2008
FDA funding approved
The US House Agriculture subcommittee has approved funding of $2.1bn for the FDA in 2009 - $282m more than the agency originally requested.
Health Imaging
Avid joins PER-C6 network
Avid Biosciences will be the pre-approved contract manufacturer for licensees of DSM and Crucell's PER.C6 cell line located in the western US.
RTT News
DHS notifies high risk facilities
The US Department of Homeland Security (DHS) is informing the owners that 7000 chemical facilities have been designated as "high risk" in the face of terrorism attack. SOCMA has welcomes the DHS action to secure chemical facilities according to risk under its Chemical Facility Anti-Terrorism Act Standards.
HS Today
Monday, 23 June 2008
Thursday, 19 June 2008
CEFIC and DSM criticise EU API measures
CEFIC and DSM have said the European Commission's proposals for tackling counterfeit APIs do not go far enough. Responding to the public consultation both parties believe APIs in medicines destined for the EU market must comply with GMP and that there are concerns over some APIs originating from India and China.
In-Pharma Technologist
Dishman builds in China
Dishman Pharmaceuticals has invested $10m in an API and intermediates facility in Shanghai, China. The facility which is due onstream early in 2009 will support Dishman's contract manufacturing business.
Sify
Monday, 16 June 2008
FDA considers outsourcing inspections
The US FDA is looking to outsource the inspection of pharmaceutical manufacturing facilities. However, there are concerns after the relative failure of a similar system used for medical devices.
San Diego Union-Tribune
Further production boost for PER-C6
DSM And Crucell have further enhanced the productivity of their PER-C6 human cell line. Just three months after announcing the cells could produce 15g/l they have announced that they can achieve production levels of 27g/l.
Reuters
Thursday, 12 June 2008
Daiichi to acquire Ranbaxy stake
Japanese pharmaceutical company Daiichi Sankyo will acquire a controlling stake in Indian generics manufacturer Ranbaxy for $4.6bn. Analysts believe the deal may start a string of western takeovers in the Indian pharmaceutical sector. Ranbaxy is believed to have talked to other companies including Takeda, GlaxoSmithKline and Pfizer. Sources suggest Pfizer may bid for a further stake in Ranbaxy.
AFP
Times of India
Business Standard
pecter slams Administration over FDA cash
Just days after the Bush Administration called on he US Congress to authorise an additional $275m for the FDA, Senator Arlen Specter has criticised the timing in the Administration Request. Specter believes the FDA needs the money asap, but the Administration request would deliver the money in March or April 2009. Specter is highly critical in his letter to Secretary Leavitt.
Wall Street Journal
Arch buys into Benzochem
Arch Pharmalabs has acquired 70% of Benzochem Lifesciences for around $23m. Benzochem specialises in manufacturing oncology products.
In-Pharma Technologist
Administration asks for more cash for FDA
US Health and Human Services Secretary Michael Leavitt has asked Congress to give the FDA an additional $275 million in next year’s budget to enhance the safety of food and medical products.
New York Times
Matthey takes stake in Dr Reddy's subsidiary
Johnson Matthey is to buy a 49% stake in Macred India, the subsidiary of Dr Reddy's dedicated to the manufacture of narcotic drugs from opium.
Economic Times
Thursday, 5 June 2008
Central Glass acquires Girindus business
Girindus has sold its Halle-Kuensebeck, Germany, process development, upscaling, cGMP production of active pharmaceutical ingredients as well as the fine chemical business and all related analytical activities to Central Glass Germany.
Girindus
CVC wins Evonik race, IPO planned
CVC Capital Partners has won the race to acquire a stake in Evonik. The private equity house has acquired a 25.01% stake in the German industrial Group for €2.4bn. Wilhelm Bonse-Geuking, CEO of Evonik's parent company, the RAG Foundation, said that RAG plans to IPO Evonik after mid-2010 and before 2013.
CVC
Bloomberg
Hemscott
Tuesday, 3 June 2008
CVC expected to win Evonik race
As the Evonik decision day draws closer, it has been revealed that RAG now plans to sell a 25.01% stake in Evonik, giving the buyer a veto vote. Reports suggest that CVC Capital Partners is the winning bidder. CVC is set to pay €2.4bn for the stake, beating bids from Bain Capital, Blackstone Group and Kohlberg Kravis Roberts.
iii
Reuters
Sunday, 1 June 2008
Evonik decision due 11 June
Evonik's parent company RAG will decide on 11 June which of the four interested financial buyers will get the 25% stake in the company. Sources suggest the workers union liked the presentations from KKR.
Forbes
Subscribe to:
Posts (Atom)
